ICON Public Limited Company
🇩🇪XFRA.IJFGermanyNot reported
Price€152.55+3.75 (+2.52%)
Latest anomalies
Very negative 38 detected in the last 120 days
- High: 13
- Medium: 22
- Low: 3
12-1M momentum: flipped sign, from negative to positive
Volume: a spike above the 20-day average
12-1M momentum: flipped sign, from negative to positive
12-1M momentum: flipped sign, from negative to positive
Working capital turnover: a sudden drop below its trailing quarter average
Free with a Finzer account.
Profile
- Germany
Identity
- Exchange
- Frankfurt Stock Exchange . XFRA
- Type
- Stock
- ISIN
- IE0005711209
- CUSIP
- Not reported
Company
- Employees
- 40,200
- Headquarters
- Dublin, Germany
- Website
- https://www.iconplc.com
Market
- Shares outstanding
- 77.2M
- Market cap
- €11.77B
Key dates
- Next earnings
- Oct 21, 2026
Highlights
- Market cap
- €11.77B
- EPS LTM
- -$2.81calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- Not reported
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- $8.37B+3.03%up year on year
- Net income
- -$216.99M-126.42%down year on year
- Gross margin
- 23.93%-16.9%down year on year
- Free cash flow
- $435.99M-55.94%down year on year
Latest news
News is not sourced for this exchange.
Business summary
ICON Public Limited Company is listed on Frankfurt Stock Exchange (Germany) under the ticker IJF. Its market capitalisation is €11.77B, from 77.2M shares outstanding, as of . Across the 252 trading sessions to the shares traded between €66.26 and €170.30, and the last close of €152.55 sits 83% of the way up that range. The company is headquartered in Dublin, Germany, and employs about 40,200 people. This is the Frankfurt Stock Exchange listing of ICON Public Limited Company; its primary listing is IJF on Stuttgart Stock Exchange.
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.